Insight journal - Dealtalk

AstraZeneca and Pfizer in the news for another possible m&a bid

Posted on 01 September 2014

Tags: , , ,

AstraZeneca stock rose two percent to £45.67 pounds yesterday after the Swedish newspaper Dagens Industry suggested another possible Pfizer m&a  bid. AstraZeneca stocks have risen 9.5% in the last week, following a stream of good news regarding its pipeline and takeover bids by Pfizer. The month of August has been rife with rumors regarding a another Pfizer takeover, targets including GlaxoSmithKline and Actavis. At least part of the most recent speculation is related to the August 26th date, which was the earliest Pfizer could make a private bid for AstraZeneca after its rebuffed acquisition bid earlier this year. Despite the rumors, at this time Pfizer has not made any public indication they intend to revisit the AstraZeneca bid with a higher offer.

AstraZeneca, meanwhile, has recently moved a promising drug from its pipeline, MEDI-4736 to a mid-stage study for colorectal cancer. A Phase III study for non-small cell lung cancer  with MEDI-4736 was initiated in May of this year. MEDI-4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), which is used by tumors to hide from the body’s immune system. MEDI-4736 blocks the signaling molecules tumors use to hide, which should help the body’s immune system attack the cancer cells. In the new study for colorectal cancer, the drug will be tested in 48 patients. The study is sponsored by Memorial Sloan-Kettering Cancer Center and is a collaboration between AstraZeneca and MedImmune LLC.

AztraZeneca also had recently announced positive results from a Phase III trial of an investigation antibiotic, ceftazidime-avibactaim, a treatment for adult hospitalized patients with complicated intra-abdominal infections. New antibiotic development is rare and would be good news for the company if it made it to the market. Similarly, if effective for colorectal cancer and other cancers, MEDI-4736 would have to potential to be “a potentially multi-blockbuster opportunity,” according to UBS analysts. Colorectal cancer is the third leading cause of cancer deaths in the U.S. In the U.S., the lifetime risk of developing colorectal cancer is about 5%, or 1 in 20. In the U.S. in 2014 about 50,310 people are expected to die of the disease.

For further deal information visit Current Agreements (subscription required)

View previously rejected offer statement

 

Related

View: Current Partnering Insight Journal's Dealtalk

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
e79banner300x150gif
e78banner300x150animgif